Showing results (1071-1080 of 1,142) with videos related to

Sort By:
Pageof 115
Viruses|November 24, 2022
Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health DisordersHeiner Wedemeyer, Vito Di Marco, Montserrat Garcia-Retortillo, et al.
Journal of Viral Hepatitis|March 7, 2018
Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in EuropeG V Papatheodoridis, A Hatzakis, E Cholongitas, et al.
Gut|July 12, 2014
Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in CaucasiansPauline Arends, Milan J Sonneveld, Roeland Zoutendijk, et al.
Molecular Metabolism|January 24, 2025
Novel translational mouse models of metabolic dysfunction-associated steatotic liver disease comparable to human MASLD with severe obesityKatharina L Hupa-Breier, Heiko Schenk, Alejandro Campos-Murguia, et al.
Plos One|July 30, 2014
Anti-HDV IgM as a marker of disease activity in hepatitis deltaAnika Wranke, Benjamin Heidrich, Stefanie Ernst, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 1, 2017
Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN)Anika Wranke, Lourdes M Pinheiro Borzacov, Raymundo Parana, et al.
JHEP Reports : Innovation in Hepatology|September 18, 2024
HBV-related HCC development in mice is STAT3 dependent and indicates an oncogenic effect of HBxMarc Ringelhan, Svenja Schuehle, Maarten van de Klundert, et al.
The New England Journal of Medicine|June 22, 2023
A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis DHeiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto, et al.
Journal of Hepatology|April 12, 2026
144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and posttreatment results from a Phase 3 randomized trialHeiner Wedemeyer, Soo Aleman, Antje Blank, et al.
Frontiers in Immunology|November 28, 2022
Immune escape pathways from the HBV core18-27 CD8 T cell response are driven by individual HLA class I allelesAndreas Walker, Tatjana Schwarz, Janine Brinkmann-Paulukat, et al.
Pageof 115